CTLA4 and lung carcinoma: Our in vivo studies showed that SB-3CT, an MMP2/9 inhibitor, could improve the efficacy of anti-PD-1 and anti-CTLA4 treatment in mouse models with melanoma and lung cancer, as well as metastatic melanoma in the lung.